Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension
AbstractNanoparticles have been used as a novel drug delivery system. Drug-incorporated nanoparticles for local delivery might optimize the efficacy and minimize the side effects of drugs. The efficacy and safety of intratracheal administration of prostacyclin analog (beraprost) -incorporated nanoparticles and imatinib (a PDGF-receptor tyrosine kinase inhibitor) -incorporated nanoparticles in Sugen-hypoxia-normoxia or monocrotaline rat models of pulmonary arterial hypertension (PAH) and in human PAH-pulmonary arterial smooth muscle cells have been reported. The use of inhaled drug-incorporated nanoparticles might be a novel approach for the treatment of PAH. View Full-Text
Share & Cite This Article
Nakamura, K.; Matsubara, H.; Akagi, S.; Sarashina, T.; Ejiri, K.; Kawakita, N.; Yoshida, M.; Miyoshi, T.; Watanabe, A.; Nishii, N.; Ito, H. Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension. J. Clin. Med. 2017, 6, 48.
Nakamura K, Matsubara H, Akagi S, Sarashina T, Ejiri K, Kawakita N, Yoshida M, Miyoshi T, Watanabe A, Nishii N, Ito H. Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension. Journal of Clinical Medicine. 2017; 6(5):48.Chicago/Turabian Style
Nakamura, Kazufumi; Matsubara, Hiromi; Akagi, Satoshi; Sarashina, Toshihiro; Ejiri, Kentaro; Kawakita, Norifumi; Yoshida, Masashi; Miyoshi, Toru; Watanabe, Atsuyuki; Nishii, Nobuhiro; Ito, Hiroshi. 2017. "Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension." J. Clin. Med. 6, no. 5: 48.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.